Juno Therapeutics, Inc. (Nasdaq: JUNO) announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE